Class A capsid assembly modulator RG7907 clears HBV-infected hepatocytes through core-dependent hepatocyte death and

Dieudonné Buh Kum1,2, Hannah Vanrusselt1, Abel Acosta Sanchez3

  • 1Aligos Belgium BV, Leuven, Belgium.

Insights

New capsid assembly modulators (CAM-As) like RG7907 trigger hepatitis B virus core protein aggregation, leading to infected cell death and potential functional cure. This mechanism offers a promising strategy for chronic hepatitis B treatment.

Area of Science:

  • Hepatology
  • Virology
  • Immunology

Background:

  • Chronic hepatitis B lacks effective functional cure therapies.
  • Capsid assembly modulators (CAM-As) are a promising therapeutic modality.
  • CAM-As induce hepatitis B virus (HBV) core protein (HBc) aggregation, reducing HBsAg levels.

Purpose of the Study:

  • To investigate the mechanism of action of the CAM-A compound RG7907.
  • To elucidate how HBc aggregation leads to viral clearance and potential functional cure.

Main Methods:

  • In vitro and in vivo studies using hepatoma cells, primary hepatocytes, and an adeno-associated virus (AAV)-HBV mouse model.
  • Treatment with RG7907.
  • Analysis of HBc aggregation, viral markers (HBsAg, HBeAg), episomal DNA, liver enzymes, apoptosis, proliferation, and gene expression via RNA sequencing.

Main Results:

  • RG7907 induced extensive HBc aggregation in vitro and in cells.
  • In vivo, RG7907 treatment significantly reduced serum HBsAg and HBeAg.
  • Liver showed clearance of HBsAg, HBc, and AAV-HBV episomes, with transient increases in liver enzymes, apoptosis, and proliferation markers, linked to interferon signaling.
  • HBc aggregation was directly linked to apoptosis and loss of infected hepatocytes.

Conclusions:

  • HBc aggregation by CAM-As induces apoptosis, leading to hepatocyte turnover and loss of HBV DNA.
  • An induced innate immune response may assist this process.
  • This mechanism represents a novel and promising strategy for a functional cure of chronic hepatitis B.
Abstract